Get key Q3 2025 earnings insights for Insulet (PODD): record revenue, robust growth in Type 1/Type 2 markets, upgraded guidance, and innovation updates.

Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery ...

Insulet reported Omnipod revenue of $699.2 million for the third quarter of 2025, up 31% over the same quarter in 2024 ...

Insulet Corporation recently reported strong third quarter results, with revenue and earnings surpassing analyst expectations and the company raising its full-year revenue and margin guidance. Key ...

Insulet Corporation (NASDAQ: PODD), best known for its Omnipod insulin delivery system, is emerging as a compelling ...

Insulet stock shed its early gains Thursday, sliding into the red, despite broadly beating sales forecasts for its insulin ...

Medical device maker Insulet on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily ...

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics ...

Insulet has launched a new campaign, “The Day Diabetes Showed Up to Work,” in honor of Diabetes Awareness Month in November.

Following the strong performance, Insulet raised its full-year 2025 revenue growth guidance to 28-29% in constant currency, up from its previous outlook of 24-27%. The company also increased its gross ...

Insulet’s recent earnings call paints a picture of robust performance and strategic growth, marked by record revenue achievements and significant market expansion. The sentiment was overwhelmingly ...